Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease
Johansson, Per LU ; Aberg, Daniel ; Johansson, Jan-Ove ; Mattsson, Niklas ; Hansson, Oskar LU
; Ahrén, Bo
LU
; Isgaard, Jorgen
; Aberg, N. David
; Blennow, Kaj
LU
and Zetterberg, Henrik
, et al.
(2013)
In Psychoneuroendocrinology
38(9).
p.1729-1737
- Abstract
- Background: Although insulin-like growth factor-I (IGF-I) is of importance for the adult function of the central nervous system (CNS), little is known of the significance of IGF-I in cerebrospinal fluid (CSF) in relation to Alzheimer's disease (AD). Methods: A cross-sectional study of 60 consecutive patients under primary evaluation of cognitive impairment and 20 healthy controls. The patients had AD dementia or mild cognitive impairment (MCI) diagnosed with AD dementia upon follow-up (n = 32), stable MCI (SMCI, n = 13), or other dementias (n = 15). IGF-I, IGF-binding protein-3 (IGFBP-3), and insulin were measured in serum and CSF. Results: Serum IGF-I level was increased in AD patients and in patients with other dementias compared to... (More)
- Background: Although insulin-like growth factor-I (IGF-I) is of importance for the adult function of the central nervous system (CNS), little is known of the significance of IGF-I in cerebrospinal fluid (CSF) in relation to Alzheimer's disease (AD). Methods: A cross-sectional study of 60 consecutive patients under primary evaluation of cognitive impairment and 20 healthy controls. The patients had AD dementia or mild cognitive impairment (MCI) diagnosed with AD dementia upon follow-up (n = 32), stable MCI (SMCI, n = 13), or other dementias (n = 15). IGF-I, IGF-binding protein-3 (IGFBP-3), and insulin were measured in serum and CSF. Results: Serum IGF-I level was increased in AD patients and in patients with other dementias compared to healthy controls (P = 0.01 and P < 0.05, respectively). Serum IGFBP-3 concentration was increased in AD and SMCI patients compared to controls (P = 0.001 and P < 0.05, respectively). CSF levels of IGF-I and IGFBP-3 as well as serum and CSF levels of insulin were similar in all study groups. In the total study population (n = 80), serum levels of IGF-I and IGFBP-3 correlated negatively with CSF beta-amyloid(1-42) (A beta(1-42)) level (r = -0.29, P = 0.01 and r = -0.27, P = 0.02, respectively) and in the AD patients (n = 32), the increased CSF/serum IGF-I ratio correlated positively with the CSF level of phosphorylated tau protein (P-tau; r = 0.42, P = 0.02). Conclusion: Patients with AD as well as other dementias had high levels of IGF-I in serum but not in CSF. In AD patients, the IGF-I system was associated with biomarkers of AD disease status. (C) 2013 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4170491
- author
- Johansson, Per
LU
; Aberg, Daniel
; Johansson, Jan-Ove
; Mattsson, Niklas
; Hansson, Oskar
LU
; Ahrén, Bo
LU
; Isgaard, Jorgen
; Aberg, N. David
; Blennow, Kaj
LU
and Zetterberg, Henrik
, et al. (More)
- Johansson, Per
LU
; Aberg, Daniel
; Johansson, Jan-Ove
; Mattsson, Niklas
; Hansson, Oskar
LU
; Ahrén, Bo
LU
; Isgaard, Jorgen
; Aberg, N. David
; Blennow, Kaj
LU
; Zetterberg, Henrik
; Wallin, Anders
and Svensson, Johan
(Less)
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- IGF-I, IGFBP-3, Insulin, Cerebrospinal fluid, Alzheimer's disease, Mild, cognitive impairment, AD biomarker
- in
- Psychoneuroendocrinology
- volume
- 38
- issue
- 9
- pages
- 1729 - 1737
- publisher
- Elsevier
- external identifiers
-
- wos:000325188300027
- scopus:84883656318
- pmid:23473966
- ISSN
- 1873-3360
- DOI
- 10.1016/j.psyneuen.2013.02.006
- project
- Endocrine and diagnostic aspects of cognitive impairment
- IGF-I and human disease; Betydelsen av IGF-I för sjuklighet hos människa
- language
- English
- LU publication?
- yes
- id
- 7ec83c4c-bcb7-4dab-aaf3-da5e08928e23 (old id 4170491)
- date added to LUP
- 2016-04-01 10:55:29
- date last changed
- 2024-01-07 04:19:42
@article{7ec83c4c-bcb7-4dab-aaf3-da5e08928e23,
abstract = {{Background: Although insulin-like growth factor-I (IGF-I) is of importance for the adult function of the central nervous system (CNS), little is known of the significance of IGF-I in cerebrospinal fluid (CSF) in relation to Alzheimer's disease (AD). Methods: A cross-sectional study of 60 consecutive patients under primary evaluation of cognitive impairment and 20 healthy controls. The patients had AD dementia or mild cognitive impairment (MCI) diagnosed with AD dementia upon follow-up (n = 32), stable MCI (SMCI, n = 13), or other dementias (n = 15). IGF-I, IGF-binding protein-3 (IGFBP-3), and insulin were measured in serum and CSF. Results: Serum IGF-I level was increased in AD patients and in patients with other dementias compared to healthy controls (P = 0.01 and P < 0.05, respectively). Serum IGFBP-3 concentration was increased in AD and SMCI patients compared to controls (P = 0.001 and P < 0.05, respectively). CSF levels of IGF-I and IGFBP-3 as well as serum and CSF levels of insulin were similar in all study groups. In the total study population (n = 80), serum levels of IGF-I and IGFBP-3 correlated negatively with CSF beta-amyloid(1-42) (A beta(1-42)) level (r = -0.29, P = 0.01 and r = -0.27, P = 0.02, respectively) and in the AD patients (n = 32), the increased CSF/serum IGF-I ratio correlated positively with the CSF level of phosphorylated tau protein (P-tau; r = 0.42, P = 0.02). Conclusion: Patients with AD as well as other dementias had high levels of IGF-I in serum but not in CSF. In AD patients, the IGF-I system was associated with biomarkers of AD disease status. (C) 2013 Elsevier Ltd. All rights reserved.}},
author = {{Johansson, Per and Aberg, Daniel and Johansson, Jan-Ove and Mattsson, Niklas and Hansson, Oskar and Ahrén, Bo and Isgaard, Jorgen and Aberg, N. David and Blennow, Kaj and Zetterberg, Henrik and Wallin, Anders and Svensson, Johan}},
issn = {{1873-3360}},
keywords = {{IGF-I; IGFBP-3; Insulin; Cerebrospinal fluid; Alzheimer's disease; Mild; cognitive impairment; AD biomarker}},
language = {{eng}},
number = {{9}},
pages = {{1729--1737}},
publisher = {{Elsevier}},
series = {{Psychoneuroendocrinology}},
title = {{Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease}},
url = {{http://dx.doi.org/10.1016/j.psyneuen.2013.02.006}},
doi = {{10.1016/j.psyneuen.2013.02.006}},
volume = {{38}},
year = {{2013}},
}